We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M Turnover 44%
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+22.21%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,043.31%
AUM
$303M
AUM Growth
-$35.4M
Cap. Flow
-$5.7M
Cap. Flow %
-1.88%
Top 10 Hldgs %
52.11%
Holding
73
New
15
Increased
24
Reduced
14
Closed
16
Avg Time Held Equity + Options
0.8 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.7 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.8 years

Sector Composition

Rank Sector Weight
1 Healthcare 91.47%
2 Miscellaneous 8.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.5B
$25M 8.24%
300,000
– –
2023 Q1
1 quarter
TGTX icon
2
TG Therapeutics
TGTX
$9.6B
$20.5M 6.77%
825,000
-275,000
-25% -$7.1M
2023 Q1
1 quarter
MLTX icon
3
MoonLake Immunotherapeutics
MLTX
$942M
$16.8M 5.56%
330,000
+135,000
+69% +$3.63M
2023 Q1
1 quarter
AKRO icon
4
DELISTED
Akero Therapeutics
AKRO
$16.8M 5.55%
360,000
+85,000
+31% +$3.9M
2022 Q4
2 quarters
APLS icon
5
DELISTED
Apellis Pharmaceuticals
APLS
$16.4M 5.41%
180,000
+15,380
+9% +$1.33M
2021 Q3
7 quarters
PCVX icon
6
Vaxcyte
PCVX
$8.77B
$14M 4.62%
280,000
+55,000
+24% +$2.61M
2021 Q2
8 quarters
RVNC icon
7
DELISTED
Revance Therapeutics
RVNC
$13.3M 4.39%
525,000
+275,000
+110% +$8.57M
2022 Q3
3 quarters
MDGL icon
8
Madrigal Pharmaceuticals
MDGL
$8.81B
$12.7M 4.19%
55,000
+25,000
+83% +$6.77M
2022 Q3
3 quarters
AMLX icon
9
Amylyx Pharmaceuticals
AMLX
$3.35B
$11.9M 3.92%
550,000
+75,000
+16% +$2.03M
2022 Q3
3 quarters
VKTX icon
10
Viking Therapeutics
VKTX
$3.16B
$10.5M 3.48%
650,000
+50,000
+8% +$1.05M
2022 Q4
2 quarters
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.43B
$9.7M 3.21%
85,000
+25,000
+42% +$3.22M
2021 Q4
6 quarters
ASND icon
12
Ascendis Pharma
ASND
$16.6B
$8.92M 2.95%
100,000
-10,000
-9% -$870K
2017 Q3
23 quarters
RETA
13
DELISTED
Reata Pharmaceuticals
RETA
$8.67M 2.86%
85,000
+15,000
+21% +$1.42M
2022 Q3
3 quarters
AXSM icon
14
Axsome Therapeutics
AXSM
$6.8B
$7.9M 2.61%
110,000
-115,000
-51% -$8.48M
2022 Q1
5 quarters
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$785M
$7.33M 2.42%
350,000
+25,000
+8% +$520K
2020 Q1
13 quarters
MRTX
16
DELISTED
Mirati Therapeutics
MRTX
$7.23M 2.39%
200,000
+60,000
+43% +$2.47M
2017 Q4
22 quarters
XENE icon
17
Xenon Pharmaceuticals
XENE
$3.64B
$7.12M 2.35%
185,000
-15,000
-8% -$596K
2023 Q1
1 quarter
COGT icon
18
Cogent Biosciences
COGT
$4.65B
$6.81M 2.25%
575,000
+25,000
+5% +$287K
2020 Q4
10 quarters
PTGX icon
19
Protagonist Therapeutics
PTGX
$7.92B
$6.21M 2.05%
225,000
– –
2023 Q1
1 quarter
VRDN icon
20
Viridian Therapeutics
VRDN
$3.4B
$5.71M 1.88%
240,000
+65,000
+37% +$1.67M
2021 Q1
9 quarters
BMEA icon
21
Biomea Fusion
BMEA
$41.7M
$4.17M 1.38%
190,000
+70,000
+58% +$2.19M
2023 Q1
1 quarter
INCY icon
22
Incyte
INCY
$23.4B
$4.05M 1.34%
65,000
-10,000
-13% -$668K
2023 Q1
1 quarter
ONC icon
23
BeOne Medicines
ONC
$44.7B
$4.01M 1.32%
+22,500
New +$5.18M
2023 Q2
0 quarters
AMAM
24
DELISTED
Ambrx Biopharma Inc
AMAM
$3.92M 1.29%
238,225
-11,775
-5% -$148K
2023 Q1
1 quarter
VIR icon
25
Vir Biotechnology
VIR
$1.56B
$3.68M 1.21%
+150,000
New +$3.77M
2023 Q2
0 quarters

Similar funds

Ghost Tree Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Ghost Tree Capital held 73 positions worth $303M, down 10% from $338M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Ghost Tree Capital's Q2 2023 filing shows 15 new, 24 increased, 14 reduced and 16 closed positions. Its largest new stake was BeOne Medicines: 22,500 shares worth $4.01M. The largest sale was Axsome Therapeutics, an estimated $8.48M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 78% a quarter earlier, followed by Miscellaneous.

  • Ghost Tree Capital's largest Q2 2023 buy was BeOne Medicines: 22,500 shares worth $4.01M.
  • Ghost Tree Capital added most to Revance Therapeutics in Q2 2023, an estimated $8.57M increase.
  • Ghost Tree Capital's biggest Q2 2023 reduction was Axsome Therapeutics, cutting an estimated $8.48M.
  • Ghost Tree Capital fully exited CTI BioPharma in Q2 2023, selling an estimated $8.4M.
  • Ghost Tree Capital's ten largest holdings make up 52% of its $303M portfolio in Q2 2023.
  • Ghost Tree Capital opened 15 new positions and closed 16 in Q2 2023.
  • Ghost Tree Capital's portfolio value fell 10% quarter-over-quarter to $303M.

Based on Ghost Tree Capital's 13F filing for Q2 2023, filed 14 Aug 2023.